Publications en collaboration avec des chercheurs de Eli Lilly and Company (8)

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2012

  1. Delphi consensus on the physical health of patients with schizophrenia: Evaluation of the recommendations of the Spanish societies of psychiatry and biological psychiatry by a panel of experts

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 3, pp. 114-128

2011

  1. Clinical meaningful outcomes in schizophrenia: Remission and recovery

    Revista de Psiquiatria y Salud Mental, Vol. 4, Núm. 1, pp. 53-65

2007

  1. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study

    European Psychiatry, Vol. 22, Núm. 8, pp. 490-498

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48